Silencing of METTL3 prevents the proliferation, migration, epithelial-mesenchymal transition, and renal fibrosis of high glucose-induced HK2 cells by mediating WISP1 in m6A-dependent manner
Aging · 2024
DOI: 10.18632/aging.205401 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging, 2024. Verfasst von Yuanzhen Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Shenzhen Guangming District People’s Hospital, Guangming, Shenzhen 518000, China. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Epithelial-Mesenchymal Transition, Methyltransferases, CCN Intercellular Signaling Proteins. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Shenzhen Guangming District People’s Hospital, Guangming, Shenzhen 518000, China.
Zitieren
APA
Chen, Y., Li, P., Lin, M., Jiang, Y., Tan, G., Huang, L., & Song, D. (2024). Silencing of METTL3 prevents the proliferation, migration, epithelial-mesenchymal transition, and renal fibrosis of high glucose-induced HK2 cells by mediating WISP1 in m6A-dependent manner. Aging. https://doi.org/10.18632/aging.205401
Vancouver
Chen Y, Li P, Lin M, Jiang Y, Tan G, Huang L, et al. Silencing of METTL3 prevents the proliferation, migration, epithelial-mesenchymal transition, and renal fibrosis of high glucose-induced HK2 cells by mediating WISP1 in m6A-dependent manner. Aging. 2024. doi:10.18632/aging.205401
BibTeX
@article{Chen2024,
author = {Chen, Yuanzhen and Li, Ping and Lin, Mei and Jiang, Ying and Tan, Guiping and Huang, Lianfang and Song, Dan},
title = {Silencing of METTL3 prevents the proliferation, migration, epithelial-mesenchymal transition, and renal fibrosis of high glucose-induced HK2 cells by mediating WISP1 in m6A-dependent manner},
journal = {Aging},
year = {2024},
doi = {10.18632/aging.205401}
}
EUVIMED